UBS Global Healthcare Conference - VERACYTE INC

Financial Performance:

• Q3 results were strong despite missing Decipher volume by ~1,000 tests; achieved 27% adjusted EBITDA margin.
• Generated over $40 million in cash flow and initiated a $100 million share buyback.
• Revenue guidance for 2027 reflects mid-single-digit growth due to mix shifts (lower ASPs for ProSigna/Bladder) and collection headwinds (approx. 5,000 test mix impact), though volume growth is expected to be double-digit.
• ProSigna ASP is projected at ~$3,800 at scale, significantly higher than anticipated.
• Biopharma revenue excluded from 2027 guidance due to timing uncertainty.
• Long-term goal is maintaining 25% EBITDA margins while investing in top-line growth.

Guidance and Future Outlook:

• 2027 Decipher volume guidance reset to 12,000–15,000 tests annually, driven by normalization post-2023/24 NCCN guideline boosts and reduced low-risk patient identification.
• Current 2027 revenue run-rate (12k tests) is based on existing evidence and sales force without new catalysts; the 15k target requires new evidence/sales expansion.
• Long-term vision remains for Decipher to reach 80% market penetration (currently ~35%), implying significant future growth velocity.
• ProSigna and Bladder products (UroAmp, TrueMRD) expected to become meaningful growth drivers in 2028 and beyond, following 2027 validation and reimbursement milestones.
• Management asserts the company remains a double-digit growth business in terms of volume and patient impact despite near-term revenue normalization.

Business Segments and Product Lines:

• Decipher Prostate: Growth normalized to 12k–15k tests post-accelerators; low-risk penetration declining due to guideline changes but intermediate/high-risk categories remain robust.
• ProSigna (Breast Cancer): Launched with differentiated Optima study data; CMS reimbursement approved for Medicare (Moldy X); targeting 225,000 patient market with potential to be market leader.
• Bladder Cancer: Comprehensive portfolio including UroAmp (non-muscle invasive), Decipher Bladder, and TrueMRD (muscle invasive recurrence); all three analytes (urine, blood, tissue) covered.
• Affirma: Contributed ~34% of sales; strong performance driven by low "no-result" rates and share gains; mid-single-digit growth guided for 2027.
• M&A: Completed an acquisition with time-lag to accretion; committed to disciplined, value-accretive M&A using free cash flow.

Market and Competitive Landscape:

• Decipher market penetration at ~35% with 80% target; competitors face challenges in low-risk guideline adherence.
• Emerging competition from Digital Pathology AI (DPAI) is diverting sales team attention and testing time, requiring increased commercial investment.
• ProSigna competes in the ER+ HER2- breast cancer space with distinct evidence allowing two-thirds of high-risk women to avoid chemotherapy.
• Biopharma interest growing in whole transcriptome/genome data for bladder and breast research.
• Management notes that while DPAI exists, their strategy is to validate the science before integrating their own algorithm, maintaining complementarity with Decipher.

Risks and Challenges:

• Decipher Volume: Impact of 2023/24 NCCN guideline boosts fading and recent low-risk guideline updates reducing testable volume.
• Competitive Noise: Increased time spent by sales teams addressing DPAI conversations versus traditional Decipher value propositions.
• Reimbursement & Guidelines: Dependence on future publications and guideline changes (e.g., metastatic Decipher, low-risk Decipher, ProSigna commercial adoption) to unlock upside.
• Revenue vs. Volume Divergence: Near-term revenue growth may lag volume growth due to lower ASPs (ProSigna/Bladder) and collection headwinds.
• Execution Risk: Time required to onboard new sales reps and medical liaisons to counter competitive pressure.

Management Commentary and Tone:

• Tone is defensive regarding stock sell-off but confident in long-term fundamentals; emphasizes that Q3 was a "bump in the road" overshadowed by strong operational execution elsewhere.
• Management rejects the view that Decipher is maturing to a non-growth state, citing low penetration and continuous evidence generation.
• CFO and CEO emphasized the company's unique ability to balance strong cash generation (25% EBITDA) with significant reinvestment for growth.
• Repeatedly stated that the 2027 guide is a prudent starting point, with significant upside potential from upcoming catalysts (Metastatic, Low-risk, ProSigna, Bladder).
• Highlighted the strategic shift from single-product valuation to a diversified portfolio (Prostate, Breast, Bladder).

Analyst Questions and Answers:

• Q: Why did the Decipher miss happen if guidelines changed earlier? A: Guideline impacts take time to flow through; low-risk patient identification has structurally declined, and fewer low-risk patients are treated.
• Q: Is 12k–15k volume sustainable? A: Yes, based on current evidence; growth to 15k+ requires new catalysts and sales team expansion.
• Q: When will ProSigna contribute meaningfully? A: Significant impact expected post-2027 as commercial adoption accelerates following Optima data publication and commercial reimbursement.
• Q: How does DPAI affect VeriSight? A: Currently a distraction for sales teams; mitigated by hiring more reps and medical liaisons; long-term strategy involves potential algorithm integration once validated.
• Q: What is the timeline for Bladder growth? A: Meaningful contribution expected in 2028+ following 2027 publications for UroAmp and TrueMRD; 2027 includes proof points.
• Q: Is the company still a double-digit grower? A: Yes, specifically on volume (tests ordered) and patient impact; revenue growth is temporarily dampened by mix but will rebound as higher ASP products mature.

Other Key Points:

• VeriSight has now served millions of patients, marking a major operational milestone.
• The "no-result" rate for Affirma is a competitive differentiator, eliminating alternative commercial justifications for other tests.
• ProSigna ASP of ~$3,800 creates a potential $250–$500M market opportunity if fully penetrated in the 225,000 patient segment.
• Management is not retreating from growth investments; they are willing to spend on sales and R&D to achieve the 25% EBITDA target.
• Biopharma partnerships are a growing area of interest, leveraging the company's whole transcriptome and genome data.